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Background
Histamine-2 receptor antagonists (H2RAs) and proton pump inhibi-
tors (PPIs) are commonly used to prevent gastrointestinal tract (GI) 
hemorrhage in critically ill patients. The stronger acid suppression 
of PPIs may reduce the rate of bleeding but enhance infectious 




To evaluate the occurrence and risk factors for GI hemorrhage, 
pneumonia, and CDI in critically ill patients.
Design
Retrospective, pharmacoepidemiologic, cohort study evaluating 
patient data voluntarily submitted to the Premier Perspective data-
base (Premier Inc).
Setting. ICUs in 71 US hospitals.
Subjects. Patients 18 years or older, admitted to an ICU between 
January 1, 2003, and December 31, 2008, requiring more than 24 
hours of invasive mechanical ventilation and receiving either an 
H2RA or PPI for 48 hours or more while intubated.
Outcomes. Primary outcomes were secondary diagnoses of Interna-
tional Classification of Diseases, Ninth Revision (ICD-9)–coded GI 
hemorrhage, pneumonia, and CDI occurring 48 hours or more after 
initiating invasive ventilation.
Data analysis. Propensity score was determined where the use of 
H2RAs or PPIs was the dependent variable and the covariates of 
age, sex, admission year, primary diagnosis, ICD-9–coded disease 
states occurring within 48 hours of ICU admission, and use of cor-
ticosteroids, anticoagulants, platelet inhibitors, or total parenteral 
nutrition were the independent variables. Propensity score-adjusted 
and propensity-matched multivariate regression models were used 
to control for confounders.
Results
Of 35 312 patients, 13 439 (38.1%) received H2RAs and 21 873 
(61.9%) received PPIs. Gastrointestinal hemorrhage (2.1% vs 5.9%; 
P < .001), pneumonia (27% vs 38.6%; P < .001), and CDI (2.2% 
vs 3.8%; P < .001) occurred less frequently in the H2RA group. 
After adjusting for propensity score and covariates, odds ratios of 
GI hemorrhage (2.24; 95%CI, 1.81-2.76), pneumonia (1.2; 95%CI, 
1.03-1.41), and CDI (1.29; 95%CI, 1.04-1.64) were greater with 
PPIs. Similar results were obtained in the propensity-matched mod-
els of 8799 patients in each cohort.
Conclusions
Proton pump inhibitors are associated with greater risks of GI hem-
orrhage, pneumonia, and CDI than H2RAs in mechanically venti-
lated patients. Numerous other risk factors are apparent. These data 
warrant confirmation in comparative prospective studies.
Abstract adapted from the original provided courtesy of PubMed: 
A service of the National Library of Medicine and the National 
Institutes of Health.
Commentary
First reported 40 years ago, stress ulceration of the gastric mucosa 
is a common complication of critical illnesss1,2. Endoscopic evi-
dence of gastrointestinal (GI) mucosal damage occurs in 60–100% 
of intensive care unit (ICU) patients and occult bleeding occurs 
in 15–50% of those with ulcerations3. Clinically overt bleeding is 
seen in 5–25% of patients not receiving prophylaxis and is associ-
ated with increased mortality and higher costs4. As a consequence, 
acid blockade to prevent stress ulceration has become a mainstay of 
preventive care in the ICU3.
The most frequently used agents for this purpose are histamine-2 
receptor antagonists (H2RAs) and proton pump inhibitors (PPIs). 
Yet which of these two agents is preferable remains an unan-
swered question. A higher pH, as can typically be achieved with 
PPIs, is associated with less gastric erosion and more effective 
topical clotting3,5,6. However a high pH is also associated with bac-
terial overgrowth in the GI tract, potentially leading to increased 
infectious risk, particularly for pneumonia and Clostridium difficile 
infection (CDI)7,8. This tension creates a tradeoff between the 
two agents, whereby PPIs may be more effective at preventing GI 
bleeding but also more likely to cause nosocomial infections9.
Several randomized controlled trials (RCTs) tried to resolve this 
tension by directly comparing PPIs to H2RAs, but were underpow-
ered for differences in patient centered outcomes. Meta-analyses 
of these RCTs generally showed that PPIs are associated with 
lower bleeding risk, but did not demonstrate an overall mortality 
reduction and were unable to examine CDI risk10–13. Differences 
in bleeding were also much smaller in higher quality studies10. 
Despite these inconclusive data, the Surviving Sepsis Campaign 
Guidelines published in 2012 and endorsed by 29 professional soci-
eties recommended the use of PPIs rather than H2RAs for stress 
ulcer prophylaxis14.
The recent study by Maclaren and colleagues15 attempts to illuminate 
this issue using the tools of pharmacoepidemiology, an emerging 
science that exploits large observational datasets to determine the 
effectiveness and safety of drugs. Since pharmacoepidemiological 
studies are observational rather than experimental, they are prone 
to confounding and indication biases. However, they are typically 
large, making them powered to detect even small treatment effects 
and represent “real world” scenarios, making them more generaliz-
able than most randomized trials.
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In the Maclaren study the authors used the Premier Perspective 
Database, the largest inpatient drug utilization database in the U.S., 
to compare the effectiveness of H2RAs and PPIs among mechani-
cally ventilated patients16. Eligible patients included adult ICU 
patients who were mechanically ventilated for at least 24 hours 
and received either an H2RA or PPI for more than 48 hours. The 
investigators excluded patients admitted with GI bleeding or who 
received both types of acid suppression, and performed propensity 
score-adjusted and matched multivariate regression models to con-
trol for confounders. The primary outcomes were diagnoses of GI 
hemorrhage, pneumonia and CDI occurring at least 48 hours after 
the institution of mechanical ventilation. The key study findings 
were higher risks for GI hemorrhage, pneumonia and CDI in the 
PPI group as compared to the H2RA group.
The increased risk of GI bleeding in patients receiving PPIs is perhaps 
the most surprising study result. One potential mechanism offered 
by the authors is that H2RAs may ameliorate the oxidative stress 
after mucosal injury. This explanation is probably unlikely given that 
PPIs also mitigate ischemia-reperfusion in gastric ulcers17,18, and the 
bulk of clinical evidence demonstrates decreased acid production 
with PPIs3,10. A perhaps more plausible explanation is misclassifica-
tion bias. Inaccuracies in data coding might have led to the inclu-
sion of patients receiving PPIs as treatment for bleeding rather than 
prevention. Additionally, it is possible that among the 4,000 patients 
excluded from the study because they received both agents, some 
began on H2RAs and then were switched to PPIs after a bleed, thus 
artificially lowering the observed incidence of bleeding in the H2RA 
group. More consistent with the previous literature is that PPIs were 
associated with increased risk of pneumonia and CDI19,20.
This study has several limitations that are common to all observa-
tional studies. In particular there is potential for unmeasured con-
founding by severity of illness, as might occur if PPI users were 
sicker and thus more prone to bleeding and infections unrelated to 
PPI use. The authors attempted to overcome this problem using a 
propensity score for the use of PPI. Although propensity scores can 
create balanced groups, it is still possible that the groups differed 
in systematic ways, since propensity scores can only account for 
measured variables21.
Despite these limitations, this study challenges the dogma that PPIs 
are associated with a lower risk of GI hemorrhage in mechanical 
ventilation. This study also supports previous investigations dem-
onstrating a link between PPIs and increased risk of pneumonia, 
and for the first time convincingly demonstrates an association with 
higher Clostridium difficile infection risk in critically ill patients.
Recommendation
Given the limitations of current meta-analyses and the lack of 
high-quality RCT data, it is time for an appropriately powered ran-
domized study comparing these two classes of acid-suppression 
agents for stress ulcer prophylaxis. Such a study should be powered 
not only for GI bleeding and infection but also for overall mortality, 
since data on GI bleeding and infection alone would not allow us 
to weigh those two competing risks. This trial might also include a 
group that would receive no prophylaxis at all if the patient toler-
ates enteral feeding. In the meantime, clinicians opting to provide 
stress ulcer prophylaxis should consider their own beliefs about the 
risks and attributable mortality of both bleeding and infections, as 
either drug can be justified as the agent of choice given the avail-
able literature. Yet at the same time, guidelines’ recommendations 
endorsing PPIs are probably premature.
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